Top Markets
#1 Cortex Cortex +32.85%
#2 EXOD EXOD +9.04%
#3 Solstice Solstice +7.20%
#4 MarsCoin MarsCoin +7.14%
#5 peaq peaq +5.99%
#6 Official Trump Official Trump +5.88%
#7 DexNet DexNet +5.76%
#8 Versatize Coin Versatize Coin +5.26%
#9 aelf aelf +4.66%
#10 Utya Utya +4.66%
Coin of the day
Cortex Cortex
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Intellia Therapeutics, Inc. Intellia Therapeutics, Inc.

Intellia Therapeutics, Inc.

NTLA
Classifica tra le azioni #6828
Intellia Therapeutics, Inc. is a biotechnology firm dedicated to advancing... Intellia Therapeutics, Inc. is a biotechnology firm dedicated to advancing therapeutic treatments through its expertise in genome editing. The company's pipeline includes several in vivo (administered within the body) programs. NTLA-2001 is currently undergoing a Phase 1 clinical trial for transthyretin amyloidosis, while NTLA-2002 targets hereditary angioedema. Additionally, Intellia is developing various other liver-focused therapies for conditions such as hemophilia A and B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo (processed outside the body) pipeline features NTLA-5001, a candidate for acute myeloid leukemia. The company is also progressing proprietary programs focused on creating engineered cell therapies to address diverse oncological and autoimmune disorders. At the core of Intellia's technology is the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has established multiple licensing and collaboration agreements. These include a partnership with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for treating sickle cell disease, and a co-development agreement with Regeneron Pharmaceuticals, Inc. for potential products against hemophilia A and B. The company also collaborates with Ospedale San Raffaele and holds a strategic alliance with SparingVision SAS to develop novel genomic medicines for ocular diseases, leveraging CRISPR/Cas9 technology. The company, initially known as AZRN, Inc., was founded in 2014 and operates from its headquarters in Cambridge, Massachusetts.
Prezzo delle azioni
$13.15
Ultima sincronizzazione: 2026-08-27
Capitalizzazione di mercato
$1.84B
Variazione (1 giorno)
-0.31%
Variazione (1 anno)
13.35%
Paese
US
Scambia Intellia Therapeutics, Inc. (NTLA)

Categoria

Healthcare
Storico dividendi per Intellia Therapeutics, Inc. (NTLA)
Intellia Therapeutics, Inc. (simbolo azionario: NTLA) ha effettuato un totale di 0 pagamenti di dividendi.
La somma totale dei dividendi (rettificata per split azionari) è: 0.00
Rendimento da dividendo (TTM): 0
Pagamenti dei dividendi per Intellia Therapeutics, Inc. (NTLA) dal 2026 al 2026
Pagamenti annuali dei dividendi
Anno Dividendo (rettificato per split azionari) Cambia
Non abbastanza dati per le date fornite.
Elenco di tutti i pagamenti di dividendi
Anno Dividendo Cambia
Non abbastanza dati per le date fornite.
Dividendi di aziende simili o concorrenti
Azienda Numero di pagamenti di dividendi Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
64.00%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
0.00%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH